{
    "nct_id": "NCT05217446",
    "official_title": "A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF ENCORAFENIB AND CETUXIMAB PLUS PEMBROLIZUMAB VERSUS PEMBROLIZUMAB ALONE IN PARTICIPANTS WITH PREVIOUSLY UNTREATED BRAF V600E-MUTANT, MSI H/DMMR METASTATIC COLORECTAL CANCER",
    "inclusion_criteria": "* Locally confirmed microsatellite instability-high/ deficient mismatch repair (MSI-H/dMMR) stage IV colorectal carcinoma\n* Locally confirmed BRAF V600E mutation in tumor tissue or blood\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Have not received prior systemic regimens for metastatic disease.\n* Measurable disease per RECIST 1.1\n* Adequate organ function\nHealthy volunteers allowed\nMust have minimum age of 16 Years",
    "exclusion_criteria": "* Colorectal adenocarcinoma that is RAS mutant or for which RAS mutation status is unknown\n* Known active central nervous system metastases and/or carcinomatous meningitis; leptomeningeal disease\n* Immunodeficiency or active autoimmune disease requiring systemic treatment in the past 2 years\n* Presence of acute or chronic pancreatitis\n* Clinically significant cardiovascular diseases (eg, thromboembolic or cerebrovascular accident events â‰¤ 12 wks prior)\n* Received a live or live-attenuated vaccine within 30 days of planned start of study medication\n* Previous treatment with any selective BRAF inhibitor (eg, encorafenib, dabrafenib, vemurafenib, XL281/BMS-908662) or any epidermal growth factor receptor (EGFR) inhibitor (eg, cetuximab, panitumumab).\n* Previous treatment with an immune checkpoint inhibitor (eg, anti-programmed cell death [PD-1], anti-PD-L1 or anti-PD-L2 agent); or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX 40, CD137).",
    "miscellaneous_criteria": ""
}